Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
2 Magnificent Dividend Stocks to Buy Right Now
01:00pm, Tuesday, 26'th Sep 2023
High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth prospe
Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs
11:17am, Tuesday, 26'th Sep 2023
Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.
Novo Nordisk and Valo Health to Use AI to Develop Treatments for Cardiometabolic Diseases
04:35pm, Monday, 25'th Sep 2023
Denmark's Novo Nordisk (NVO) struck a deal with U.S.-based health tech firm Valo Health to use artificial intelligence (AI) to discover and develop treatments for cardiometabolic diseases such as hear
Morgan Stanley sees biopharma sector as a 'safe haven'
10:01am, Monday, 25'th Sep 2023
Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over
Novo Nordisk announces AI collaboration with Valo Health for cardiometabolic treatments
09:51am, Monday, 25'th Sep 2023
Novo Nordisk (NYSE:NVO) has announced a collaboration with Valo Health to discover and develop novel treatments for cardiometabolic using Valo's artificial intelligence (AI)-powered Opal Computational
Novo Nordisk partners with Valo Health on AI drug discovery
08:28am, Monday, 25'th Sep 2023
Novo Nordisk NVO, +0.01% on Monday announced a partnership with Valo Health Inc., a technology company specializing in AI-powered drug discovery and development, to focus on new cardiometabolic drug p
The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. There could be reduced demand for junk food and increased demand for athletic brands.
Where Will Novo Nordisk Stock Be in 5 Years?
09:53am, Friday, 22'nd Sep 2023
Revenue is up 29% this year as Wegovy and Ozempic have been in high demand. Sales could go even higher as the company sorts out manufacturing issues.
Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
08:30am, Friday, 22'nd Sep 2023
Novo Nordisk shares reached all-time highs in September but have since dropped nearly 10%. Buyers must question whether peak optimism has been priced in. With an "F" valuation grade, it isn't the time
Why Novo Nordisk Stock Was Tumbling on Thursday
03:56pm, Thursday, 21'st Sep 2023
An analyst reiterated his recommendation and price target. Unfortunately, that recommendation is the equivalent of a sell.
Why Novo Nordisk Stock Edged Higher Today
05:08pm, Wednesday, 20'th Sep 2023
The company inked yet another supply deal with a European healthcare tech specialist. Also, an analyst reiterated his buy recommendation on the Wegovy maker.
Novo Nordisk: What The Stock Split Means For Traders And Investors
11:53am, Wednesday, 20'th Sep 2023
Danish diabetes care giant Novo Nordisk is splitting its shares, with the Danish-listed B shares splitting on September 13 and the NYSE-listed ADRs splitting on September 20. This split marks a milest
Flee to Healthcare Stocks if Recession Rears its Head?
07:04am, Wednesday, 20'th Sep 2023
If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
Ypsomed signs autoinjector supply deal with Novo Nordisk
03:20am, Wednesday, 20'th Sep 2023
Swiss medical technology company Ypsomed announced on Wednesday a long-term supply agreement with Novo Nordisk for autoinjectors, as the Danish drugmaker struggles to keep up with demand for its new W
Novo Nordisk to establish insulin production in South Africa
08:42am, Tuesday, 19'th Sep 2023
Novo Nordisk (NYSE:NVO) wants to produce insulin in South Africa along with a partner to treat diabetics across the African continent, it said. In a statement, the Danish pharmaceutical giant said it
